Amgen

News

Relief for AZ, Amgen as FDA okays severe asthma hope tezepel...

The FDA has approved AstraZeneca and Amgen's severe asthma hope tezepelumab, exonerating the drugmakers' decision to press ahead with a regulatory filing despite a failed phase 3 trial.

News

FDA sets Sept review date for BMS' psoriasis drug deucravaci...

The FDA has kicked off its review of Bristol-Myers Squibb's psoriasis therapy deucravacitinib, setting an action date of 1 September next year, as the EU and Japanese regulators also start

News

Merck's oral PCSK9 drug matches injectables in early trials

Injectable antibodies targeting PCSK9 have failed to take off as expected in the cholesterol-lowering market, but Merck & Co hopes to do much better with an oral alternative.

News

Failed IBD trial dents confidence in BMS' deucravacitinib

Bristol-Myers Squibb's hopes of extending the use of its highly-anticipated psoriasis pill deucravacitinib into inflammatory bowel disease (IBD) have been hit by a mid-stage failure in ulce

News

ICER says Amgen's tezepelumab 'likely to be too expensive'

Amgen and AstraZeneca haven't won approval or announced a price for their severe asthma therapy tezepelumab should it reach the market, but the ICER in the US maintains it will probably not

News

ESMO21: First combo data with Amgen's Lumakras hit the mark ...

Amgen has made progress with its plans to expand the use of its first-in-class KRAS inhibitor Lumakras, reporting encouraging results when the drug is used alongside its EGFR drug Vectibix

Relief for AZ, Amgen as FDA okays severe asthma hope tezepel...

FDA sets Sept review date for BMS' psoriasis drug deucravaci...

Merck's oral PCSK9 drug matches injectables in early trials

Failed IBD trial dents confidence in BMS' deucravacitinib

ICER says Amgen's tezepelumab 'likely to be too expensive'

ESMO21: First combo data with Amgen's Lumakras hit the mark ...

Repligen builds in cell therapy with $1.5bn BioLife takeover

Discover a new era of healthcare panel engagement: Grounded ...

Amgen

Editor's Picks